

## Final Announcement:

# Impact of the COVID-19 pandemic on clinical trials

Wednesday, June 16, 2021, 2-4 pm CET


## Virtual Seminar

The COVID-19 pandemic has disrupted many ongoing clinical trials. The BBS held its first seminar on pandemic impacts and possible mitigation strategies on May 6, 2020. More than a year later, first practical experiences with the implementation of mitigation steps and their acceptability by health authorities have been gained. We therefore kindly invite you to a second seminar on this important topic featuring case studies, regulatory experiences, and theoretical advances.

Organizing committee: Hans Ulrich Burger, Roche; Achim Güttner, Novartis; Lilla DiScala, Janssen; Marcel Wolbers, Roche

## Program

<b>14:00-14:05</b>	<b>Welcome</b> Hans Ulrich Burger, BBS president Marcel Wolbers, Roche
<b>14:05-14:30</b>	<b>Overview on early experience of the impact of Covid-19 pandemic on clinical trials</b> Anja Schiel, Chair Scientific Advice Working Party, EMA
<b>14:30-14:50</b>	<b>COVID-19 pandemics : Impact on Clinical Trials in a chronic progressing disease</b> Paul Delmar, Roche
<b>14:50-15:10</b>	<b>Hypothetical strategy for a case study affected by COVID-19 pandemic</b> Eva Hua, Novartis
<b>15:10-15:35</b>	<b>The hypothetical estimand and its potential estimators in clinical trials impacted by COVID-19</b> Kelly Van Lancker, Ghent University
<b>15:35-16:00</b>	<b>Panel discussion</b> All presenters Moderated by Achim Güttner, Novartis



## Venue

Virtual event

## Registration

The event is for free but registration is mandatory. Please register via the following

[link](#)